Mycosis fungoides secondary prevention

	Mycosis fungoides Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mycosis Fungoides from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
X-Ray
CT Scan
MRI
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mycosis fungoides secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mycosis fungoides secondary prevention All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mycosis fungoides secondary prevention
CDC on Mycosis fungoides secondary prevention
Mycosis fungoides secondary prevention in the news
Blogs on Mycosis fungoides secondary prevention
Directions to Hospitals Treating Mycosis fungoides
Risk calculators and risk factors for Mycosis fungoides secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

There are no established measures for the secondary prevention of mycosis fungoides.

There are no established measures for the secondary prevention of mycosis fungoides.

Effective measures for the secondary prevention of mycosis fungoides include:^[1]^[2]
- Effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.
- Phototherapy (PUVA and involves oral 8-methoxypsoralen) is the preservation in the early stage.

↑ Santos JL (June 1974). "[Projection of the Brazilian population: 1970-2000]". Rev Saude Publica (in Portuguese). Suppl: 91–102. PMID 4438970.
↑ Willemze, R; Hodak, E; Zinzani, P L; Specht, L; Ladetto, M (2018). "Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†". Annals of Oncology. 29 (Supplement_4): iv30–iv40. doi:10.1093/annonc/mdy133. ISSN 0923-7534.